TELA Bio, Inc. markets innovative OviTex reinforced tissue matrices combining ovine-derived biologic material with polymer fibers for hernia repair and soft-tissue reconstruction. The company’s growth is supported by FDA clearances, clinical validation, a focused U.S. direct sales effort, and contracts with national GPOs and IDNs that enhance hospital penetration. Despite persistent net losses exceeding $38 million in 2025 [F1], TELA Bio benefits from a stable supply agreement with Aroa and invests in R&D for product enhancements. Its $60 million indebtedness with restrictive covenants imposes financial constraints, challenging the path to profitability amid evolving regulatory and competitive pressures [S1][S6][S7].